

DMARDs Offer Cardiac Protection to RA Patients

BY SALLY KOCH KUBETIN
Publication Editor

SAN FRANCISCO — The increased risk for cardiovascular disease associated with the diagnosis of rheumatoid arthritis was offset by the protective effects of disease-modifying antirheumatic drugs but heightened by prednisolone therapy in a large community-based study.

The study used data on individuals registered in the United Kingdom General Practice Research Database who were treated for rheumatoid arthritis between 1987 and 2002. This period predates the widespread use of anti-tumor necrosis factor (TNF) agents, so the findings offer no information on whether these agents are protective against cardiovascular disease, Dr. Christopher J. Edwards said at the

While prednisolone has similarly strong anti-inflammatory effects in RA, these effects do not translate into protection against cardiovascular disease.

annual meeting of the American College of Rheumatology.

The research involved about 35,000 individuals diagnosed with RA and compared their rates of myocardial infarction (as a surrogate marker for cardiovascular disease) with those of 100,000 matched healthy controls.

The incidence of MI in patients with RA was 6.49/1,000 person-years vs. 2.96/1,000 person-years for controls.

The incident rate ratio was increased for MI by an RA diagnosis (2.23), according to a Poisson regression analysis. The increased risk persisted even after a multifactor regression analysis controlled for traditional cardiovascular disease risk factors, including age, BMI, sex, smoking, serum lipid levels, hypercholesterolemia, and hypertension.

Of the 966 patients with RA who had an MI during the study period, 705 (73%) received treatment with either a disease-modifying antirheumatic drug (DMARD) or prednisolone during that time.

Of these 705, a total of 538 took either DMARDs or prednisolone within the 2 months that immediately preceded their MI.

The incident rate ratio for MI among patients on either a DMARD or prednisolone, compared with those not on these agents, was 0.94. Further analysis of DMARDs showed that the individual incident rate ratio for hydroxychloroquine, methotrexate, and sulfasalazine vs. no drug were 0.42, 0.67, and 0.69, respectively. In contrast, use of prednisolone vs. no drug was associated with an incident rate ratio of 1.49. The effect sizes remained similar after controlling for traditional cardiovascular disease risks but were no longer significant.

The strong anti-inflammatory effects of DMARDs are the likely explanation of their protective effect against MI, Dr. Edwards said in an interview. Data from a

number of trials have shown that these agents lower C-reactive protein (CRP) levels. It is reasonable but still pure conjecture to conclude that lowering CRP levels in RA patients lowers the risk of cardiovascular disease, said Dr. Edwards, consultant rheumatologist and senior lecturer at Southampton University Hospital (England).

While prednisolone has similarly strong anti-inflammatory effects in RA, these effects do not translate into protection

against cardiovascular disease. Prednisolone use is associated with increased blood pressure and serum lipids levels and weight gain, which offset any anti-inflammatory benefits for the cardiovascular system, he continued in the interview.

In contrast to data presented by Dr. Edwards, findings from the recent QUEST-RA (Quantitative Patient Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis) study show that prednisolone was protective against car-

diovascular disease in RA (Ann. Rheum. Dis. 2007;66:1491-6). As an explanation for the conflicting findings, Dr. Edwards suggested that the difference may be that the patients in the British cohort had earlier RA and were more susceptible to the adverse effects of prednisolone than were the cohort patients in QUEST-RA, all of whom were referred to the study from tertiary care centers with advanced RA.

Dr. Edwards reported he has no conflict of interest concerning this research. ■

Thanks!



For making us America's #1 Joint Care Brand.†

We can't thank doctors enough for recommending Osteo Bi-Flex® to their patients. Now, doctors can feel even better about recommending Osteo Bi-Flex because it is the only joint care brand with Joint Shield™. Joint Shield is specially formulated with 5-Loxin® to help patients control joint flare-ups.* Taking 5-Loxin showed improvement in joint

comfort within 7 days! Plus, Osteo Bi-Flex has the naturally sourced Glucosamine and Chondroitin that help lubricate and cushion joints*. Osteo Bi-Flex is clinically tested and manufactured under the strictest standards for product purity and potency. It's no wonder doctors recommend Osteo Bi-Flex more than any other joint care brand.‡

Free Sample Kit.**

Call 1-888-848-2435 or visit www.osteobiflex.com to receive your free patient samples of Osteo Bi-Flex and for a free copy of "The Science Behind Osteo Bi-Flex."

†These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

‡Based on the results of the National Disease and Therapeutic Index syndicated report among physicians who recommend a branded Glucosamine/Chondroitin or Glucosamine supplement, December 2006.

**Allow 6-8 weeks for delivery. While supplies are in stock.

†This statement is based on a recent human study, using an objective measure. (Biomarker analysis)

©2007 Rexall Sundown, Inc. 021507ds